Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Doses of Sufenidone in Healthy Volunteers
NCT06135363Phase 1Completed
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sufenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Incidence and severity of adverse events and serious adverse events related drug. Started Aug 2022; status: completed.
02
Drugs
sufenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06135363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135363.